These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32118317)

  • 1. Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: Methods, simulation model and their implementation in R.
    Friede T; Stallard N; Parsons N
    Biom J; 2020 Sep; 62(5):1264-1283. PubMed ID: 32118317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations.
    Schmidli H; Bretz F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):635-43. PubMed ID: 16972715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim decision making in seamless trial designs: An application in an adaptive dose-finding study in a rare kidney disease.
    Papachristofi O; Bornkamp B; Wright M; Friede T
    Pharm Stat; 2024; 23(1):20-30. PubMed ID: 37691560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive designs for confirmatory clinical trials with subgroup selection.
    Stallard N; Hamborg T; Parsons N; Friede T
    J Biopharm Stat; 2014; 24(1):168-87. PubMed ID: 24392984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive seamless designs with interim treatment selection: a case study in oncology.
    Carreras M; Gutjahr G; Brannath W
    Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
    Mossop H; Grayling MJ; Gallagher FA; Welsh SJ; Stewart GD; Wason JMS
    Br J Cancer; 2022 Feb; 126(2):204-210. PubMed ID: 34750494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov.
    Bothwell LE; Avorn J; Khan NF; Kesselheim AS
    BMJ Open; 2018 Feb; 8(2):e018320. PubMed ID: 29440155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical characteristics of adaptive design in phase 2 and 3 clinical trials.
    Sato A; Shimura M; Gosho M
    J Clin Pharm Ther; 2018 Apr; 43(2):170-180. PubMed ID: 28850685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis.
    Friede T; Parsons N; Stallard N; Todd S; Valdes Marquez E; Chataway J; Nicholas R
    Stat Med; 2011 Jun; 30(13):1528-40. PubMed ID: 21341301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.
    Bretz F; Schmidli H; König F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):623-34. PubMed ID: 16972714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical Trial.
    Cerqueira FP; Jesus AMC; Cotrim MD
    Ther Innov Regul Sci; 2020 Jan; 54(1):246-258. PubMed ID: 32008232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup.
    Sugitani T; Posch M; Bretz F; Koenig F
    Stat Med; 2018 Oct; 37(24):3387-3402. PubMed ID: 29945304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seamless phase II/III designs.
    Stallard N; Todd S
    Stat Methods Med Res; 2011 Dec; 20(6):623-34. PubMed ID: 20724313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive design implementation in confirmatory trials: methods, practical considerations and case studies.
    Li Q; Lin J; Lin Y
    Contemp Clin Trials; 2020 Nov; 98():106096. PubMed ID: 32739496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive seamless designs: selection and prospective testing of hypotheses.
    Jennison C; Turnbull BW
    J Biopharm Stat; 2007; 17(6):1135-61. PubMed ID: 18027222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive Dunnett tests for treatment selection.
    Koenig F; Brannath W; Bretz F; Posch M
    Stat Med; 2008 May; 27(10):1612-25. PubMed ID: 17876763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing Issues in Confirmatory Adaptive Population Enrichment Trials.
    Wassmer G; Dragalin V
    J Biopharm Stat; 2015; 25(4):651-69. PubMed ID: 24905739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.